Dr. Chad E. Travers, MD
Cardiology (Cardiovascular Disease Physician)
1600 S 48th St, Ste 600
Lincoln, NE 68506
Who else practices at this address →
Lancaster County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Nebraska College of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 2,743
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: University of Nebraska College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
NE license 26784 -
Internal Medicine Physician
IL license 125-051415
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Bryan Medical Center Lincoln, NE
- Columbus Community Hospital, Inc Columbus, NE
- Nemaha County Hospital Auburn, NE
- Syracuse Area Health Syracuse, NE
- Johnson County Hospital Tecumseh, NE
Medical groups
- Integrated Cardiology Group LLC (77 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 2,743
- Services billed
- 4,773
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,750 | 1,220 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 834 | 761 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 597 | 583 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 257 | 251 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 213 | 140 |
| New patient office or other outpatient visit, 45-59 minutes | 170 | 170 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 169 | 169 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 112 | 112 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 93 | 93 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 75 | 61 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 28 payments worth $507 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $83.53 |
|---|---|
| Novartis Pharmaceuticals Corporation | $79.61 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $76.57 |
| AstraZeneca Pharmaceuticals LP | $67.20 |
| Pfizer Inc. | $48.99 |
| Alnylam Pharmaceuticals Inc. | $39.18 |
| Scpharmaceuticals Inc. | $35.70 |
| Medtronic, Inc. | $23.80 |
| Food and Beverage | $507 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $156,785 in research payments for these studies, mostly to the institutions running them.
- A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Amgen Inc. - TRANSFORM
Cleerly, Inc. - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Amgen Inc. - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Amgen Inc. - OCEAN(a)-Outcomes Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction Outcomes trial
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.